Macular Degeneration

Abstract

Macular degeneration is the progressive deterioration of the macula, the small central patch of retina that carries fine detail, colour, reading, and face recognition. Age-related macular degeneration is the leading cause of severe central vision loss in older adults. Its interest for perception is the exact inverse of glaucoma: where glaucoma quietly erodes the periphery, macular degeneration attacks the centre — the region used to fixate — so the deficit is anything but silent. This article treats macular degeneration as a worked case in central vision: the cone-dense fovea and why its loss is so costly, the central scotoma that swallows whatever a person looks at directly, the eccentric viewing and preferred retinal locus the brain improvises to read around it, the metamorphopsia and Charles Bonnet hallucinations it produces, and the reading and quality-of-life burden that follows.

Keywords: macula, central scotoma, fovea, eccentric viewing, preferred retinal locus

Macular degeneration names a family of diseases that share a target: the macula lutea, the central few millimetres of retina where the cone photoreceptors are packed most densely and where the eye resolves its finest detail (Mitchell et al., 2018). The common, age-related form — age-related macular degeneration, or AMD — is a disease of ageing in which metabolic waste accumulates beneath the retina, the supporting tissue fails, and the central photoreceptors die, either slowly, as geographic atrophy, or abruptly, when abnormal new vessels leak and bleed (Fleckenstein et al., 2021). It is the leading cause of irreversible central vision loss in the developed world; population studies since the Beaver Dam Eye Study established how steeply its prevalence climbs with age (Klein et al., 1992), and by one widely cited projection some 288 million people will be affected by 2040 (Wong et al., 2014). What makes it a subject for cognitive psychology is not the retina but the perception: it removes precisely the vision people use to read, recognise faces, and fixate a target, while leaving the periphery intact — a dissociation that reshapes how a person sees the world and, sometimes, what they hallucinate into it.

What Macular Degeneration Is

Macular degeneration is the loss of central vision caused by deterioration of the macula, the specialised central region of the retina responsible for high-acuity, detailed sight (Mitchell et al., 2018). The macula is small — a patch a few millimetres across at the centre of the retina — but it does a disproportionate share of the work of seeing: it holds the fovea, where the cone photoreceptors are most densely packed, and it is the only part of the retina that resolves the fine spatial detail reading and face recognition demand. When the macula degenerates, that central detail is lost, and because the disease spares the rest of the retina, the peripheral field survives. The result is a person who can walk across a room and see its shape and motion but cannot read the clock on its wall or recognise the face of the person sitting across it.

The age-related form is by far the most common, and it develops in two courses that the clinical literature separates sharply (Ferris et al., 2013). The early and intermediate stages are marked by drusen — yellowish deposits of metabolic waste that accumulate beneath the retinal pigment epithelium, the support layer that nourishes the photoreceptors. Most disease then follows the dry, or atrophic, path: the pigment epithelium and overlying photoreceptors slowly waste away, and in advanced dry AMD this produces geographic atrophy, expanding islands of dead retina that erase central vision gradually over years (Fleckenstein et al., 2021). A minority of cases convert to the wet, or neovascular, form, in which fragile new blood vessels grow up from beneath the retina, leak fluid and blood, and can destroy central vision over days to weeks if untreated (Ambati & Fowler, 2012). The wet form is the more dramatic and, historically, the more blinding, but it is now the more treatable.

A first sign patients themselves can catch is distortion. Because the disease lifts and buckles the delicate central retina before it destroys it, straight lines begin to look bent or wavy — a symptom called metamorphopsia — and a small patch of the central scene may go missing or grey. The Amsler grid, a simple square of ruled lines with a central fixation dot, is the classic home test for exactly this: a person covers one eye, looks at the dot, and reports whether the lines around it wave, blur, or vanish. It is a direct, low-tech readout of the macula's failing map of central space.

Types of Macular Degeneration

In the MeSH classification, macular degeneration sits beneath retinal degeneration and branches into several narrower descriptors. Listing them is a matter of how the clinical and research literature is indexed rather than a clean theory of how the disease divides at its joints: MeSH is an indexing vocabulary, the subtypes below are not mutually exclusive, and the split that matters most day to day — between the age-related dry and wet forms — cuts across this list rather than aligning with it. Several children here are in fact distinct inherited or secondary conditions grouped with age-related macular degeneration only because they, too, damage the macula. With that caveat, the direct MeSH subtypes are the following.

The division that matters most for the age-related disease is the one that does not appear as a single pair of MeSH terms: dry versus wet. That distinction determines the treatment — anti-VEGF injections for the wet form, and, for advanced dry disease, only recently the first therapies that modestly slow atrophy — and it is the axis the rest of this article follows. The inherited dystrophies grouped above (Stargardt, vitelliform) share the macular target but differ in cause, onset, and genetics; what unites every subtype for our purposes is the perceptual consequence, a central scotoma, which is where the psychology begins.

The Macula and the Cost of Central Vision

To see why macular degeneration is so disabling, look at how vision is distributed across the retina. Acuity is not uniform: it is extraordinarily high at the fovea, the tiny pit at the centre of the macula where cones are packed at their maximum density and each has almost its own private line to the brain, and it falls off steeply with every degree of eccentricity away from that centre (Mitchell et al., 2018). This is why the eyes must point directly at a word to read it: only the fovea has the resolving power, and the rest of the retina, however healthy, cannot substitute. The peripheral retina is built for a different job — detecting motion, sensing dim light, taking in the broad layout of a scene — and it is comparatively blind to fine detail.

Figure 1

Why a Central Lesion Costs So Much: The Acuity Gradient and the Scotoma It Destroys

That gradient is the whole tragedy of macular degeneration. The disease destroys exactly the sliver of retina that carries acuity and leaves intact the vast surround that cannot. A patient may retain a nearly full visual field by area and still be legally blind for reading, because the small central region that resolves letters is gone. It is the precise complement of glaucoma, which spares the acuity-bearing centre until last while hollowing out the periphery: the two diseases carve the visual field along opposite lines, and their perceptual consequences are correspondingly opposite — glaucoma steals mobility while sparing reading, macular degeneration steals reading while sparing mobility.

The steepness of the acuity falloff also sets a hard ceiling on adaptation. When the fovea is lost, the best a person can do is view eccentrically, using a patch of surviving parafoveal retina — but that patch, being off-centre, has intrinsically lower resolution, so the vision it delivers is limited no matter how well the person learns to use it. The Worked Example below puts numbers to that ceiling; the demonstration here shows the falloff directly.

Eccentric Viewing and the Preferred Retinal Locus

The central scotoma of macular degeneration has a peculiar and defining property: it moves with the gaze. Because the blind region sits at the fovea, it lands wherever the person points their eyes, so it obscures precisely the thing they are trying to look at. Turn to read a word and the scotoma covers the word; turn to see a face and it covers the face. This is the opposite of an ordinary obstacle in the field, which can be looked around; the macular scotoma cannot be looked around, because it is the point of looking.

The visual system's response to this is one of the most striking examples of perceptual plasticity in the clinic. Rather than continuing to aim the useless fovea at targets, many patients spontaneously develop a preferred retinal locus — a patch of intact retina, just outside the scotoma, that they adopt as a new pseudo-fovea and learn to point at what they want to see (Crossland et al., 2005). Eccentric viewing of this kind is the foundation of low-vision rehabilitation: a person is taught to look slightly to the side of a target so that its image falls on the preferred locus rather than into the blind centre. The adaptation is real and useful, and it develops over months, but it is bounded by the acuity ceiling of the section above — the preferred locus is off the fovea, so it can never restore foveal resolution, only recover some functional reading from an eccentric patch that has more resolving power than none.

Reduced resolution is not the only limit on eccentric reading, and here the cognitive psychology of peripheral vision adds a second constraint the acuity model alone misses: visual crowding. In peripheral vision, a letter that is perfectly resolvable in isolation becomes unidentifiable when flanked by other letters, because nearby contours are pooled together and the target is lost in the clutter — a limit on object recognition rather than on acuity, and one that grows far more severe with eccentricity than acuity loss alone predicts (Whitney & Levi, 2011). Crowding is why a person using a preferred retinal locus can often make out a single large letter yet still read continuous text painfully slowly: the letters interfere with one another. It is also why perceptual-learning regimens that train eccentric reading can raise reading speed beyond what the raw acuity of the locus would allow, by teaching the periphery to cope with crowded text (Chung, 2011).

The demonstration below makes the two states concrete: a target seen through a gaze-locked central scotoma, and the same target recovered by shifting fixation so it lands on a preferred retinal locus off to the side.

The Psychology of Central Vision Loss

Because macular degeneration takes the specific vision that reading, writing, and face recognition depend on, its psychological toll is out of proportion to the area of retina it destroys. The inability to read is consistently among the losses patients rate as most distressing, and the disease is associated with markedly reduced quality of life, loss of independence, and elevated rates of depression; a systematic review of real-world function found impairment across reading, mobility, daily activities, and emotional well-being that tracks the central deficit rather than any measure of the peripheral field (Taylor et al., 2016). The loss of face recognition is particularly isolating: a person can no longer read the expressions that carry the emotional content of a conversation, or recognise friends until they speak, which corrodes social confidence in ways an acuity chart does not capture.

The most cognitively remarkable consequence, however, is not what patients cannot see but what some of them do see. A substantial fraction of people with macular degeneration experience the Charles Bonnet syndrome: vivid, formed visual hallucinations — patterns, figures, faces, scenes — occurring in people who are visually impaired but cognitively intact and who typically know the images are not real (Menon et al., 2003). The syndrome is best understood as the visual cortex's response to deprivation: when the macula stops sending signals, the deprived cortical territory does not fall silent but generates activity of its own, which is experienced as hallucination — a release phenomenon closely analogous to the phantom limb. It is a direct demonstration that perception is generated as much as received, and that removing the input to a cortical region can unmask, rather than merely subtract, its activity. Clinically, the most important fact about Charles Bonnet hallucinations is that they are benign and not a sign of psychiatric or cognitive disease; patients who are simply told this are often greatly relieved, having feared they were losing their minds rather than only their central vision.

Worked Example

Two numbers frame the disease — one for its scale, one for the ceiling on adaptation.

Start with the burden. A widely cited meta-analysis projected that the number of people with age-related macular degeneration worldwide would rise from about 196 million in 2020 to roughly 288 million by 2040 (Wong et al., 2014). That is a growth factor of 288 ÷ 196 ≈ 1.47, an increase of about 47% in twenty years — driven almost entirely by population ageing, since the disease is strongly age-dependent. The arithmetic is a reminder that macular degeneration is not a static clinical problem but a growing public-health one, expanding roughly in step with the greying of the world's population.

The second number explains why even the best rehabilitation cannot restore reading vision. Acuity falls with eccentricity, and a useful teaching approximation models the minimum angle of resolution — the smallest gap the eye can resolve, in arcminutes — as MAR(E) ≈ MAR₀ × (1 + E ÷ E₂), where E is eccentricity in degrees from the fovea, MAR₀ ≈ 1 arcminute is foveal resolution (Snellen 20/20), and E₂ ≈ 2.5° is the eccentricity at which acuity has halved. A preferred retinal locus adopted at, say, 10° from the dead fovea therefore resolves at MAR = 1 × (1 + 10 ÷ 2.5) = 1 × 5 = 5 arcminutes. Snellen acuity scales with MAR, so 5 × (20/20) corresponds to about 20/100 — the target must be five times larger than a normally sighted person needs. Move the locus closer to the old fovea, to 5°, and the model gives MAR = 1 × (1 + 5 ÷ 2.5) = 3 arcminutes, about 20/60; push it out to 15° and it falls to MAR = 7, roughly 20/140. This is the ceiling eccentric viewing runs into: the closer a viable preferred locus sits to the lost fovea the better, but no eccentric patch can match foveal resolution, which is why large print, magnification, and text-to-speech — not a return to normal reading — are the realistic goals of low-vision care. (The demonstrations above use this same model, so their numbers agree with these.)

Discussion

Macular degeneration is an eye disease that becomes, on inspection, a lesson about the architecture of central vision. Its mechanism at the retina — the age-related accumulation of drusen, failure of the retinal pigment epithelium, and death of the central photoreceptors, whether by slow atrophy or by neovascular leakage — is increasingly well characterised, and for the wet form the arrival of anti-VEGF drugs was a genuine therapeutic revolution: injections of ranibizumab not only slowed but on average modestly improved vision in the pivotal trials, a result no previous treatment had approached (Rosenfeld et al., 2006; Brown et al., 2006), and later work established that far cheaper bevacizumab is comparably effective (CATT Research Group, 2011). For the dry form, the AREDS and AREDS2 trials showed that a specific antioxidant and mineral supplement slows progression to advanced disease in those at intermediate risk (Age-Related Eye Disease Study Research Group, 2001; Age-Related Eye Disease Study 2 (AREDS2) Research Group, 2013), and modifiable risk factors — smoking above all — are now well established (Heesterbeek et al., 2020).

But the reason macular degeneration is so disabling has little to do with how much retina it destroys and everything to do with which retina. It removes the acuity-bearing centre and leaves the detail-blind surround, so the field can look nearly full while reading, faces, and fixation are gone. That places the disease squarely at the boundary between ophthalmology and cognitive psychology. The gaze-locked scotoma, the improvised preferred retinal locus, the eccentric-viewing training that low-vision rehabilitation is built on, the release hallucinations of the Charles Bonnet syndrome, and the reading-centred quality-of-life burden are all facts about perception and its plasticity, not about the retina alone. Macular degeneration is a standing demonstration that the value of a piece of retina is set by what the brain does with it — and that losing a few square millimetres at the exact centre can cost more than losing most of the rest.

Current Directions

The most active fronts in macular degeneration research target the two forms unevenly, reflecting where the unmet need now lies. For the long-untreatable dry form, the major recent advance is the arrival of complement-inhibiting drugs that modestly slow the enlargement of geographic atrophy, the first treatments to touch the atrophic disease at all — an outgrowth of the inflammatory and complement-pathway account of AMD pathogenesis that has reframed the molecular understanding of the disease (Ambati & Fowler, 2012; Fleckenstein et al., 2021). A second thread aims to reduce the enormous treatment burden of the wet form, where monthly or near-monthly eye injections are a heavy load on patients and clinics: longer-acting anti-VEGF agents and sustained-delivery implants seek to extend the interval between treatments (Guymer & Campbell, 2023). A third front is prevention and prediction — refining the classification and risk-stratification of early disease so that the people most likely to progress can be identified before central vision is lost (Ferris et al., 2013; Heesterbeek et al., 2020) — alongside earlier-stage work on retinal cell replacement and gene therapy for the inherited macular dystrophies. Across all of it, the global-health framing is explicit: the burden is large and growing, and much of the effort is oriented toward detecting and slowing the disease at population scale (Wong et al., 2014).

Common Misconceptions

Macular degeneration causes total blindness.

It destroys central vision but spares the peripheral field, so people retain navigational and mobility vision even when they can no longer read or recognise faces. It is a leading cause of severe central loss, not of complete darkness (Mitchell et al., 2018).

Seeing vivid images means dementia or psychiatric illness.

The formed visual hallucinations of the Charles Bonnet syndrome are common in macular degeneration and occur in cognitively intact people who know the images are unreal. They are a release phenomenon of deprived visual cortex, not a sign of madness (Menon et al., 2003).

Nothing can be done about it.

Anti-VEGF injections transformed the wet form, often preserving or improving vision; supplements slow progression in intermediate dry disease; and complement inhibitors now modestly slow geographic atrophy. Early detection and low-vision rehabilitation change outcomes (Rosenfeld et al., 2006; Age-Related Eye Disease Study 2 (AREDS2) Research Group, 2013).

The two forms are just mild and severe versions of one thing.

Dry and wet AMD differ in mechanism and course: dry disease is slow atrophy driven by waste accumulation and cell death, while wet disease is abrupt neovascular leakage. Either can be advanced and blinding, and dry disease can convert to wet (Ambati & Fowler, 2012; Fleckenstein et al., 2021).

Glossary

Amsler grid.

A ruled square with a central fixation dot used to detect macular disease; a patient reports whether the lines near the centre appear wavy, blurred, or missing, giving a direct readout of central distortion and scotoma.

Anti-VEGF therapy.

Treatment of wet macular degeneration by injecting drugs that block vascular endothelial growth factor, the signal driving the abnormal new vessels; it can preserve and often improve central vision.

Central scotoma.

A blind or degraded region at the centre of the visual field; because it sits at the fovea it moves with the gaze and obscures whatever the person looks at directly, the defining perceptual deficit of macular degeneration.

Charles Bonnet syndrome.

Vivid, formed visual hallucinations occurring in visually impaired but cognitively intact people who recognise the images as unreal; a release phenomenon of visual cortex deprived of input.

Crowding.

The failure to identify an object, such as a letter, when it is flanked by others in peripheral vision, even when the same object is easily recognised in isolation; a limit on object recognition rather than acuity, and a major constraint on eccentric reading in macular degeneration.

Drusen.

Yellowish deposits of metabolic waste that accumulate beneath the retinal pigment epithelium; their number and size are the hallmark of early and intermediate age-related macular degeneration.

Eccentric viewing.

The strategy of looking slightly to the side of a target so its image falls on surviving retina rather than into the central scotoma; the basis of low-vision reading rehabilitation.

Fovea.

The tiny central pit of the macula where cone photoreceptors are packed most densely and acuity is highest; its loss is what makes macular degeneration so costly for detailed vision.

Geographic atrophy.

The advanced stage of dry macular degeneration, in which sharply demarcated patches of retinal pigment epithelium and photoreceptors have died and slowly enlarge, erasing central vision over years.

Macula.

The central region of the retina, a few millimetres across, that carries high-acuity, detailed, colour vision; the structure whose deterioration defines macular degeneration.

Metamorphopsia.

Distortion of vision in which straight lines appear bent or wavy, caused by lifting and buckling of the central retina; often the first symptom of wet macular degeneration a patient notices.

Neovascularisation.

The growth of abnormal new blood vessels beneath the retina in wet macular degeneration; these vessels leak fluid and blood and can destroy central vision rapidly.

Preferred retinal locus.

A patch of intact retina just outside the central scotoma that a patient adopts as a new pseudo-fovea, learning to point it at targets; the perceptual substrate of eccentric viewing.

Retinal pigment epithelium.

The support layer beneath the photoreceptors that nourishes them and clears their waste; its failure is central to age-related macular degeneration, whether by atrophy or by permitting neovascular growth.

Scotoma.

A blind or partially blind area within the visual field, surrounded by seeing regions; in macular degeneration it is central and gaze-locked, hiding the point of fixation itself.

Wet (neovascular) AMD.

The form of age-related macular degeneration driven by abnormal new blood vessels leaking beneath the retina; less common than the dry form but historically more blinding, and the form transformed by anti-VEGF treatment.

Key Researchers

Jayakrishna Ambati

(contemporary). DuPont Guerry III Professor of Ophthalmology at the University of Virginia, whose work on the inflammasome and Alu-RNA toxicity reframed the molecular pathology of geographic-atrophy (dry) macular degeneration. Faculty Page - ORCID - Wikidata

Usha Chakravarthy

(contemporary). Professor of ophthalmology and vision sciences at Queen's University Belfast; led the IVAN trial comparing ranibizumab and bevacizumab and contributed to the clinical classification of the disease. ORCID - Google Scholar

Emily Y. Chew

(contemporary). Director of the Division of Epidemiology and Clinical Applications at the National Eye Institute and chair of AREDS2; led the AREDS and AREDS2 nutritional-supplement trials that define the standard of care for intermediate dry disease. Faculty Page - Google Scholar - Wikipedia

Robyn H. Guymer

(contemporary). Professor and deputy director of the Centre for Eye Research Australia at the University of Melbourne; a leader in macular-degeneration clinical research and classification and co-author of a Lancet seminar on the disease. Faculty Page - ORCID - Google Scholar - Wikipedia - Wikidata

Ronald Klein

(1945-2019). Professor of ophthalmology and visual sciences at the University of Wisconsin-Madison and co-principal investigator of the Beaver Dam Eye Study, which established modern population estimates of age-related maculopathy. Faculty Page

Paul Mitchell

(contemporary). Professor of ophthalmology at the University of Sydney and director of the Centre for Vision Research at the Westmead Institute; led the Blue Mountains Eye Study and first-authored a Lancet seminar on age-related macular degeneration. Faculty Page

Philip J. Rosenfeld

(contemporary). Professor of ophthalmology at the Bascom Palmer Eye Institute, University of Miami; pioneered anti-VEGF therapy for neovascular macular degeneration, including the off-label use of bevacizumab and the pivotal MARINA trial of ranibizumab. Faculty Page - ORCID - Google Scholar

Tien Yin Wong

(contemporary). Ophthalmologist and epidemiologist at Tsinghua Medicine, Beijing, formerly of the Singapore Eye Research Institute; senior author of the global prevalence meta-analysis and a leader in retinal-disease epidemiology and imaging. Faculty Page - ORCID - Google Scholar

Frequently Asked Questions

What is macular degeneration?

Macular degeneration is the progressive deterioration of the macula, the small central part of the retina responsible for fine detail, reading, colour, and face recognition. The most common form is age-related, and it causes loss of central vision while sparing the peripheral field (Mitchell et al., 2018).

Does macular degeneration cause total blindness?

No. It destroys central vision but leaves peripheral vision intact, so people can usually still move around and orient themselves even after they can no longer read or recognise faces. It is a leading cause of severe central vision loss, not of complete darkness (Mitchell et al., 2018).

What is the difference between dry and wet macular degeneration?

Dry (atrophic) disease is a slow wasting of the central retina driven by waste accumulation and cell death, culminating in geographic atrophy. Wet (neovascular) disease is the growth of leaky new blood vessels beneath the retina, which can destroy central vision quickly if untreated (Ambati & Fowler, 2012; Fleckenstein et al., 2021).

Can it be treated?

The wet form is treated with anti-VEGF injections that often preserve or improve vision; the dry form is slowed in at-risk people by specific antioxidant and mineral supplements, and newer complement-inhibiting drugs modestly slow geographic atrophy. None restores vision already lost (Rosenfeld et al., 2006; Age-Related Eye Disease Study 2 (AREDS2) Research Group, 2013).

Why can people with macular degeneration still walk around but not read?

Because acuity is concentrated at the fovea, the centre of the macula, and falls steeply toward the periphery. The disease destroys that acuity-bearing centre and spares the peripheral retina, which is good at motion and layout but poor at fine detail: enough for mobility, not enough for reading (Mitchell et al., 2018).

What is eccentric viewing?

It is the strategy of looking slightly to the side of a target so its image falls on surviving retina rather than into the central blind spot. Many patients develop a preferred retinal locus, a patch of intact retina used as a new pseudo-fovea, and low-vision rehabilitation trains this skill (Crossland et al., 2005).

Why do some people with macular degeneration see things that are not there?

Vivid visual hallucinations in the visually impaired are the Charles Bonnet syndrome, a common and benign consequence of visual loss in which the deprived visual cortex generates its own imagery. The people affected are cognitively intact and usually know the images are not real (Menon et al., 2003).

How common is macular degeneration?

It is the leading cause of irreversible central vision loss in the developed world, and its prevalence is rising with population ageing, with one projection estimating about 196 million people affected in 2020, growing to some 288 million by 2040 (Wong et al., 2014).

References